NCT05445219View on ClinicalTrials.gov

Identifying Therapeutic Hemodialysis Targets Through Cerebrovascular Reactivity; RESPIRACT 2

Active, not recruitingOBSERVATIONAL
Enrollment

37

Participants

Timeline

Start Date

May 20, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Kidney Failure
Interventions
DIAGNOSTIC_TEST

RespirAct

The RespirAct device is an automated breathing circuit that uses a gas bladder to control and deliver CO2 to measure cerebrovascular reactivity

Trial Locations (1)

N6A 5W9

London Health Sciences Centre, London

All Listed Sponsors
collaborator

Heart and Stroke Foundation of Canada

OTHER

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER